IR Banner

Press Releases

Date Title and Summary Additional Format
Nov 23, 2020
Lumos Pharma to Participate in December Investor Conferences
AUSTIN, Texas , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in
Nov 11, 2020
CEO Update: Getting the word out - OraGrowtH Trials
I am excited to share news about the communication program we are launching for the LUM-201 pipeline. Understanding that clinical trials conducted in the pediatric rare disease space are unique and special in nature, let me introduce you to “OraGrowtH Trials.” We believe that connecting the trials’
Nov 10, 2020
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical
Oct 29, 2020
Lumos Pharma to Participate in November Investor Conferences
AUSTIN, Texas , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in
Oct 27, 2020
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
AUSTIN, Texas , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020 .
Aug 27, 2020
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in
Aug 13, 2020
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRV Lumos Pharma reaffirms its expectation of the initiation of its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020
Jul 30, 2020
CEO Update: Lumos Pharma’s COVID-19 Response and Clinical Progress
As CEO of Lumos Pharma, Inc. , I wanted to take this opportunity to update our shareholders on the impact of the coronavirus pandemic, the company’s policies addressing this pandemic, and our preparations for returning to a more normal work environment.
Jul 28, 2020
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
AUSTIN, Texas , July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close on Thursday, August 13, 2020 .
Jul 27, 2020
Lumos Pharma Announces Sale of Priority Review Voucher
AUSTIN, Texas , July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD
Displaying 1 - 10 of 18